相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy
Ziyou Lin et al.
EMBO JOURNAL (2020)
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
Zhong-Zhe Lin et al.
ONCOLOGIST (2020)
Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study
Wei He et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Hepatic Hippo signaling inhibits development of hepatocellular carcinoma
Yuchen Liu et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2020)
Hepatocellular carcinoma: old friends and new tricks
Eunsun Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway
Yuan Zhou et al.
CANCER CELL INTERNATIONAL (2019)
Multifaceted regulation and functions of YAP/TAZ in tumors
Huirong Liu et al.
ONCOLOGY REPORTS (2018)
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Carolina Mendez-Blanco et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Hippo pathway mediates resistance to cytotoxic drugs
Taranjit S. Gujral et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Yan-jing Zhu et al.
ACTA PHARMACOLOGICA SINICA (2017)
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells
Xiao-Yang Dai et al.
ONCOTARGET (2016)
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells
Tian-yi Zhou et al.
SCIENTIFIC REPORTS (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
Jian-Jun Gao et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
APATINIB: A PROMISING ORAL ANTIANGIOGENIC AGENT IN THE TREATMENT OF MULTIPLE SOLID TUMORS
A. J. Scott et al.
DRUGS OF TODAY (2015)
Post-transplantation hepatocellular carcinoma recurrence: Patterns and relation between vascularity and differentiation degree
Annarita Pecchi et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Naveen S. Vasudev et al.
ANGIOGENESIS (2014)
Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo
Lin Zheng et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
DECADE IN REVIEW-HEPATOCELLULAR CARCINOMA HCC-subtypes, stratification and sorafenib
Gregory J. Gores
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Hepatocellular carcinoma review: Current treatment, and evidence-based medicine
Bulent Karaman et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out
Hong Sun et al.
WORLD JOURNAL OF HEPATOLOGY (2014)
Hypoxia-Mediated Sorafenib Resistance Can Be Overcome by EF24 Through Von Hippel-Lindau Tumor Suppressor-Dependent HIF-1α Inhibition in Hepatocellular Carcinoma
Yingjian Liang et al.
HEPATOLOGY (2013)
Sorafenib in liver cancer
Hyun Young Woo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality
Y Tanaka et al.
GASTROENTEROLOGY (2006)
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
HB El-Serag et al.
GASTROENTEROLOGY (2004)
分享论文
